The FDA and DEA Regulatory Landscape for Psychedelic Therapy

American psychedelic therapy lives in a suspended condition: too evidenced to dismiss, too contested to approve, and governed by two agencies whose mandates pull in opposite directions. The public conversation treats the question as settled in one direction or the other — imminent medicine or dangerous hype. This spine maps the actual regulatory landscape as a readiness problem: what would have to be true, institutionally and evidentiarily, for the threshold to be crossed, and who benefits from the threshold staying where it is.

I. The Two Gates

The argument begins with structure, not substances. The Food and Drug Administration controls what may be marketed as medicine; the Drug Enforcement Administration controls how scheduled substances may be handled at all. A psychedelic therapy must pass both, in sequence, and the gates apply different logics — one evidentiary, one enforcement-driven. This section establishes why the dual-gate architecture, not any single ruling, is the real subject of the paper, and why analyses that track only one agency systematically misread the timeline.

II. The Trial Record as Claimed

This section surveys the shape of the evidence without adjudicating it. The standard account holds that MDMA-assisted therapy for post-traumatic stress and psilocybin for depression advanced through phased trials to the edge of approval, and that an advisory committee setback for the MDMA application exposed weaknesses — functional unblinding, expectancy effects, therapy-drug confounds — that the field had preferred to describe as strengths. Every element is a claim to verify against the docket, the transcripts, and the published protocols, not a fact to repeat.

III. The Adversarial Moment

Regulatory history turns on identifiable moments, and this section isolates them: the advisory vote, the agency’s response letter, the sponsor’s reformulation. The working paper will argue that the setback was misread by both camps — neither proof of a conspiracy against psychedelics nor proof of their failure, but a demonstration that the evidentiary standard for a drug-plus-therapy hybrid had never been written before. That missing standard is the paper’s central object.

IV. Rescheduling Mechanics

Even a successful approval solves only half the problem. This section maps the rescheduling pathway: how a substance moves between schedules, what findings the statute requires, and where administrative discretion concentrates. The capture-cycle framework is introduced here — the hypothesis that scheduling functions less as pharmacology than as jurisdictional allocation, preserving enforcement equities and licensing regimes regardless of the underlying evidence. The hypothesis will be tested, not assumed.

V. The State Patchwork

Below the federal threshold, a second landscape is already operating: state-level psilocybin programs, municipal deprioritization, religious-use exemptions litigated case by case. This section argues the patchwork is not a sideshow but a natural experiment in regulatory design — and that its early difficulties, from cost to access to program solvency, are data the federal conversation is ignoring.

VI. What Readiness Would Require

The closing section converts the analysis into criteria. A defensible readiness finding would require: a written evidentiary standard for drug-therapy combinations; a rescheduling pathway with named decision points; therapist-training and diversion-control infrastructure; and a stated position on the indigenous and religious claims the medical channel displaces. Against those criteria, the paper will deliver its verdict on where the landscape actually stands.

Counter-case

The strongest opposing view is the precautionary one, and it is held by serious people. On this account, the trial record is weaker than its press: small samples, unblindable conditions, adverse-event reporting that independent critics consider inadequate, and a sponsor community with financial and ideological stakes in approval. The history of American medicine includes celebrated treatments that outran their evidence, and the therapeutic enthusiasm around psychedelics has the signature of a movement, not a finding. Under this view the regulators’ hesitation is not capture but competence, the state experiments are premature, and the burden of proof sits exactly where it belongs — on those asking to reschedule a controlled substance for millions of vulnerable patients.

Sources to verify

• The FDA complete response letter and advisory committee transcript for the MDMA application — UNVERIFIED, confirm before citing in the finished essay
• MAPS and Lykos Therapeutics published trial protocols and results — UNVERIFIED, confirm before citing in the finished essay
• The Controlled Substances Act scheduling criteria and DEA rescheduling precedents — UNVERIFIED, confirm before citing in the finished essay
• Oregon and Colorado state program reports and audits — UNVERIFIED, confirm before citing in the finished essay
• Critical analyses of psychedelic trial methodology, including unblinding and expectancy critiques — UNVERIFIED, confirm before citing in the finished essay
• Religious-use exemption litigation record under the Religious Freedom Restoration Act — UNVERIFIED, confirm before citing in the finished essay

Stakes

This spine operationalizes the capture-cycle framework on live regulatory terrain and extends the argument of the Institute’s essay They Scheduled the Cure: that American drug scheduling has repeatedly served institutional interest while wearing the language of public health. The regulatory landscape is the test case where that claim either survives contact with the docket or fails. It also grounds the Institute’s broader consciousness workstream: whether non-ordinary states can be studied, administered, and known inside American institutions is being decided now, in these two agencies, by precisely the mechanisms this paper maps.